Malignancy-related hypercalcemia developing on a bisphosphonate but responding to calcitonin

Clinical Lung Cancer

Volumn 8, Issue 7, 2007, Pages 434-435

  Diskin, Charles J ^a   Stokes, Thomas J ^a   Dansby, Linda M ^a   Radcliff, Lautrec ^a   Carter, Thomas B ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Alendronate; Furosemide; Squamous cell carcinoma

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CARBONATE; FUROSEMIDE; LOOP DIURETIC AGENT;

AGED; ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; LUNG BIOPSY; LUNG CARCINOMA; OSTEOPOROSIS; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 34547807690     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2007.n.028     Document Type: Article

References (11)

1. Edelson GW, Kleerekoper M. Hypercalcemic crisis. Med Clin North Am 1995; 79:79-92.
2. Ljunghall S, Rastad J, Akerstrom G. Comparative effects of calcitonin and clodronate in hypercalcaemia. Bone 1987; 8(suppl 1):S79-S83.
3. Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol 2000; 27:322-334.
4. Ziegler R. Hypercalcemic crisis. J Am Soc Nephrol 2001; 12(suppl 17):S3-S9.
5. Toyras A, Ollikainen J, Taskinen M, et al. Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur J Pharm Sci 2003; 19:223-230.
6. Joshua F, Epstein M, Major G. Bisphosphonate resistance in Paget's disease of bone. Arthritis Rheum 2003; 48:2321-2323.
7. Onuma E, Azuma Y, Saito H, et al. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors. Clin Cancer Res 2005; 11:4198-4203.
8. Atabek ME, Pirgon O, Sert A. Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. J Pediatr Endocrinol Metab 2006; 19:169-172.
9. Saunders Y, Ross JR, Broadley KE, et al. Systematic review of bisphosphonates for hypercalcaemia of malignancy. Palliat Med 2004; 18:418-431.
10. Papadaki HA, Tsatsanis C, Christoforidou A, et al. Alendronate reduces serum TNFalpha and IL-1beta, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis. J Bone Miner Metab 2004; 22:577-587.
11. Paillard F, Ardaillou R, Malendin H, et al. Renal effects of salmon calcitonin in man. J Lab Clin Med 1972; 80:200-216.